Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CYBIN INC. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 6-K Quarterly results
10/13/2023 6-K Quarterly results
10/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit"
10/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit"
10/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder"
09/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Small Pharma Reports Positive Top-line Data from SPL026 -SSRI Drug Interaction Study in Patients with Major Depressive Disorder"
09/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial"
08/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"CYBIN ANNOUNCES RENEWED AT-THE-MARKET EQUITY PROGRAM OF UP TO US$35 MILLION",
"Equity Distribution Agreement",
"Consent of Aird & Berlis LLP",
"Consent of Aird & Berlis LLP",
"Material Change Report"
08/18/2023 6-K Quarterly results
08/18/2023 6-K Quarterly results
08/17/2023 6-K Quarterly results
08/15/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program"
08/14/2023 6-K Quarterly results
Docs: "6-K",
"Interim Consolidated Financial Statements for the three months ended June 30, 2023",
"Management’s Discussion and Analysis for the three months ended June 30, 2023",
"Certification of Interim Filings by CFO",
"Certification of Interim Filings by CEO",
"Cybin Reports First Quarter Financial Results and Recent Business Highlights"
08/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Material Change Report",
"Material Change Report"
08/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Warrant Indenture",
"Consent of Aird & Berlis LLP",
"CYBIN ANNOUNCES CLOSING OF OVERNIGHT MARKETED PUBLIC OFFERING OF UNITS"
08/02/2023 6-K Quarterly results
08/01/2023 6-K Quarterly results
08/01/2023 6-K Quarterly results
07/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference"
07/26/2023 6-K Quarterly results
07/24/2023 6-K Quarterly results
07/20/2023 6-K Quarterly results
07/13/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT"
06/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin to Participate in PSYCH Symposium London 2023"
06/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer"
06/15/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference"
06/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin Inc. Provides Corporate Update"
06/01/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin to Present at the Jefferies Healthcare Conference"
06/01/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Material Change Report",
"Material Change Report"
05/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial"
05/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial"
04/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin to Participate at the 26th Annual Milken Institute Global Conference"
03/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference"
03/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy